Margetuximab is a recombinant monoclonal antibody designed to target human epidermal growth factor receptor 2 (HER2). It is an Fc-engineered immunoglobulin G1 (IgG1) antibody developed to enhance immune-mediated activity against HER2-expressing cancer cells.
Margetuximab binds to HER2 on tumor cells and is designed with an optimized Fc region to increase interaction with certain activating Fc gamma receptors on immune effector cells. This supports antibody-dependent cellular cytotoxicity (ADCC) as part of its antitumor mechanism.
Margetuximab is a specialized biopharmaceutical oncology API used in the development and manufacture of biologic anticancer products.
As a recombinant monoclonal antibody, its quality assessment requires extensive characterization of identity, purity, potency, aggregation, charge variants, glycosylation, protein concentration and biological activity.
CAS Number: Not typically assigned as a conventional small-molecule CAS number
Molecular Type: Recombinant Monoclonal Antibody
Antibody Class: IgG1
Target: Human Epidermal Growth Factor Receptor 2 (HER2)
Drug Class: HER2-Directed Monoclonal Antibody
Therapeutic Class: Antineoplastic Biologic
Therapeutic Area: Oncology
Development Code: MGAH22
Margetuximab binds specifically to HER2, a receptor overexpressed in certain cancers.
Its Fc-engineered structure is designed to enhance binding to activating Fcγ receptors, particularly FcγRIIIa, while reducing interaction with the inhibitory FcγRIIb.
This can enhance immune-effector mechanisms including:
Margetuximab therefore combines HER2-specific targeting with Fc-mediated immune activation.
Margetuximab is used in oncology for:
Margetuximab-cmkb is approved in combination with chemotherapy for certain patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, including at least one for metastatic disease.
Margetuximab is particularly relevant to HER2-positive breast cancer. Its engineered Fc region distinguishes it from conventional HER2-targeting antibodies by seeking to improve immune-effector-cell engagement.
Margetuximab is a recombinant glycoprotein monoclonal antibody produced using mammalian-cell expression technology.
As a biologic API, its critical quality attributes can include:
A controlled Margetuximab manufacturing process may involve:
Typical Margetuximab biologic API characterization may include:
Margetuximab drug substance should be stored under validated refrigerated conditions appropriate for the biologic, with protection from freezing, excessive heat and unnecessary light exposure. Exact storage requirements should follow the approved manufacturer specification and stability program.
Margetuximab is relevant to research involving:
Margetuximab is a recombinant Fc-engineered IgG1 monoclonal antibody targeting HER2. It is an oncology biologic developed to enhance Fc-mediated immune activity against HER2-expressing tumor cells and is associated primarily with the treatment of HER2-positive metastatic breast cancer.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |